OGN vs RYAN · P/E 3.4, rev $6.40B vs P/E 43, rev $2.46B
Organon & Co (OGN) versus Ryan Specialty Group Holdings Inc (RYAN) — a side-by-side from cached financials, not a winner call.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Ryan Specialty Group Holdings Inc (RYAN) is a insurance - specialty company listed on NYSE.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Latest reported RYAN revenue for 2024-12-31 was $2.46B. Net income was $229.9M. Revenue was up 21.2% from 2023-12-31 to 2024-12-31. RYAN currently screens at market cap $9.33B and trailing P/E 43.1.
OGN currently screens at market cap $2.52B and trailing P/E 3.4. RYAN currently screens at market cap $9.33B and trailing P/E 43.1.
Not investment advice. Open the OGN and RYAN stock pages for the full models.
Not investment advice.